Search Within

Lukas Delasos

Formats
  1. Journal Article (7)
  2. Meeting Abstract (7)
Groups
  1. Department of Pathology and Laboratory Medicine (12)
  2. Sloan Kettering Institute Postdocs (12)
  3. GSK Faculty (11)
  4. Human Oncology and Pathogenesis Program (11)
  5. Tow Center for Developmental Oncology (TCDO) (11)
  6. Department of Medicine (10)

More Groups

People
  1. Romel Somwar (12)
  2. Marc Ladanyi (11)
  3. Alexander Drilon (7)
  4. Elisa De Stanchina (7)
  5. Marissa Mattar (7)
  6. Morana Vojnic (7)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2021 (3)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Journal of Thoracic Oncology (6)
  2. Disease Models & Mechanisms (2)
  3. Annals of Oncology (1)
  4. Cancer Discovery (1)
  5. Clinical Cancer Research (1)
  6. European Journal of Cancer (1)

More Publications

Publishers
  1. Elsevier Inc. (7)
  2. American Association for Cancer Research (2)
  3. Company of Biologists (2)
  4. American Society of Clinical Oncology (1)
  5. Nature Research (1)
  6. Oxford University Press (1)

Results (14)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling
    Journal Article

    Smith, R. S.; Odintsov, I.; Liu, Z.; Lui, A. J. W.; Hayashi, T.; Vojnic, M.; Suehara, Y.; Delasos, L.; Mattar, M. S.; Hmeljak, J.; more...
    Disease Models & Mechanisms (2022)

    Fulltext@MSK | Save
  • Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers
    Journal Article

    Odintsov, I.; Mattar, M. S.; Lui, A. J. W.; Offin, M.; Kurzatkowski, C.; Delasos, L.; Khodos, I.; Asher, M.; Daly, R. M.; Rekhtman, N.; more...
    Journal of Thoracic Oncology (2021)

    Fulltext@MSK | Save
  • The anti-HER3 mAb seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions
    Journal Article

    Odintsov, I.; Lui, A. J. W.; Sisso, W. J.; Gladstone, E.; Liu, Z.; Delasos, L.; Kurth, R. I.; Sisso, E. M.; Vojnic, M.; Khodos, I.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • RET inhibition in novel patient-derived models of RET fusion-positive lung adenocarcinoma reveals a role for MYC upregulation
    Journal Article

    Hayashi, T.; Odintsov, I.; Smith, R. S.; Ishizawa, K.; Liu, A. J. W.; Delasos, L.; Kurzatkowski, C.; Tai, H.; Gladstone, E.; Vojnic, M.; more...
    Disease Models & Mechanisms (2021)

    Fulltext@MSK | Save
  • The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements
    Meeting Abstract

    Odintsov, I.; Gladstone, E.; Sisso, W. J.; Delasos, L.; Lui, A. J. W.; Sisso, E. M.; Vojnic, M.; Khodos, I.; Mattar, M. S.; de Stanchina, E.; more...
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Generation and characterization of novel preclinical disease models of NSCLC with NRG1 rearrangements to improve therapy
    Meeting Abstract

    Gladstone, E.; Vojnic, M.; Offin, M.; Delasos, L.; Lui, A.; Siau, E.; Sato, H.; Benayed, R.; Kurth, R.; Mattar, M.; more...
    Journal of Thoracic Oncology (2019)

    Fulltext@MSK | Save
  • MET inhibitor resistance in patients with MET exon 14-altered lung cancers
    Meeting Abstract

    Guo, R.; Offin, M.; Brannon, A. R.; Chow, A.; Delasos, L.; Somwar, R.; Wilkins, O.; Scott, K.; Tian, Y.; Cecchi, F.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Response to ERBB3-directed targeted therapy in NRG1-rearranged cancers
    Journal Article

    Drilon, A.; Somwar, R.; Mangatt, B. P.; Edgren, H.; Desmeules, P.; Ruusulehto, A.; Smith, R. S.; Delasos, L.; Vojnic, M.; Plodkowski, A. J.; more...
    Cancer Discovery (2018)

    Fulltext@MSK | Save
  • A phase 2 study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A.; Somwar, R.; Smith, R.; Delasos, L.; Albano, M.; Van Voorthuyson, M.; Wang, L.; Rekhtman, N.; Ni, A.; Plodkowski, A.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save